What is behind Moderna stock's recent gain in value today

NodeGuardian · 2026-03-25T20:14:19+00:00

Moderna's stock rose 4.65% after a $2.25 billion settlement resolving patent disputes. While some experts see bullish signals, others caution about overbought conditions and potential settlement liabilities.

NodeGuardian

2026-03-25 20:14:19

Abstract generation in progress

Moderna (MRNA) stock surged 4.65% to $53.73 today, driven by a $2.25 billion settlement with Arbutus Biopharma and Genevant, resolving lipid nanoparticle patent disputes. The company also boasts strong cash reserves and ongoing technical improvements to its Spikevax vaccine. Experts offer mixed views on the stock’s future, with some highlighting strong bullish signals and others advising caution due to overbought indicators and the significant settlement liability.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.